日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results

羟氯喹联合伊曲康唑治疗前列腺癌生化复发男性患者的I期研究（HITMAN-PC）：剂量递增结果

期刊:Cancer Research Communications
影响因子:3.3
doi:10.1158/2767-9764.CRC-26-0010
Talmor, Barak; Marastoni, Stefano; Lau, Brandon; Yam, Andrew O; Yeung, Nicole; Lin, Hui-Ming; Li, Zhu Juan; Woo, Henry; Pranavan, Ganes; Stricker, Phillip D; Horvath, Lisa G; Koritzinsky, Marianne; Wouters, Bradly G; Crumbaker, Megan; Joshua, Anthony M
肿瘤
前列腺癌
肿瘤免疫
发表日期：2026
文献求助 收藏

Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience

立体定向放射治疗寡转移性前列腺癌的真实世界临床结果：澳大利亚的经验

期刊:BJUI Compass
影响因子:1.9
doi:10.1002/bco2.70055
Shekar, Samantha; Crumbaker, Megan; Joshua, Anthony; Yam, Andrew; Stricker, Phillip; Yuen, Carlo; Ende, David; Namdarian, Benjamin; Thompson, James; Kooner, Raji; O'Neill, Gordon; Mo, Jeremy; Sim, Hao-Wen; Hruby, George; Kasraei, Farshad; Ho, Annie; De Leon, Jeremy
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Efficacy of systemic therapy in metastatic adrenocortical carcinoma: a meta-analysis of prospective clinical trials

系统治疗转移性肾上腺皮质癌的疗效：前瞻性临床试验的荟萃分析

期刊:Endocrine Oncology
影响因子:
doi:10.1530/EO-25-0027
Shekar, S; Hall, A; Pham, J; Crumbaker, M; Liu, J; Talmor, B; Sim, H W; Joshua, A M
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)

采用 177Lu-PSMA-I&T 治疗转移性去势抵抗性前列腺癌患者的疗效（Re-SPECT）

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359231156392
Emmett, Louise; John, Nikeith; Pathmanandavel, Sarennya; Counter, William; Ayers, Maria; Sharma, Shikha; Agrawal, Shikha; Poole, Aron; Hovey, Elizabeth; Pranavan, Ganes; Gedye, Craig; Mallesara, Girish; Guminski, Alex; Lee, Adrian; Stockler, Martin R; Hickey, Adam; Eu, Peter; Joshua, Anthony M; Crumbaker, Megan; Nguyen, Andrew
肿瘤
前列腺癌
肿瘤免疫
发表日期：2023
文献求助 收藏

The Prognostic Value of Posttreatment (68)Ga-PSMA-11 PET/CT and (18)F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with (177)Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)

在 I/II 期试验 (LuPIN) 中，采用 (177)Lu-PSMA-617 和 NOX66 治疗转移性去势抵抗性前列腺癌后，治疗后 (68)Ga-PSMA-11 PET/CT 和 (18)F-FDG PET/CT 的预后价值

期刊:
影响因子:
doi:10.2967/jnumed.122.264104
Pathmanandavel, Sarennya; Crumbaker, Megan; Nguyen, Andrew; Yam, Andrew O; Wilson, Peter; Niman, Remy; Ayers, Maria; Sharma, Shikha; Eu, Peter; Martin, Andrew J; Stockler, Martin R; Joshua, Anthony M; Emmett, Louise
肿瘤
前列腺癌
肿瘤免疫
发表日期：2023
文献求助 收藏

Evaluation of (177)Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective (177)Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

在 (177)Lu-PSMA-617 和 NOX66 联合治疗的前瞻性试验 (LuPIN) 中，评估 (177)Lu-PSMA-617 SPECT/CT 定量作为疗效生物标志物的价值

期刊:
影响因子:
doi:10.2967/jnumed.122.264398
Pathmanandavel, Sarennya; Crumbaker, Megan; Ho, Bao; Yam, Andrew O; Wilson, Peter; Niman, Remy; Ayers, Maria; Sharma, Shikha; Hickey, Adam; Eu, Peter; Stockler, Martin; Martin, Andrew J; Joshua, Anthony M; Nguyen, Andrew; Emmett, Louise
发表日期：2023
文献求助 收藏

The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors

无细胞 DNA 甲基化组可区分局限性前列腺肿瘤和转移性前列腺肿瘤

期刊:Nature Communications
影响因子:14.7
doi:10.1038/s41467-022-34012-2
Sujun Chen #, Jessica Petricca #, Wenbin Ye #, Jiansheng Guan, Yong Zeng, Nicholas Cheng, Linsey Gong, Shu Yi Shen, Junjie T Hua, Megan Crumbaker, Michael Fraser, Stanley Liu, Scott V Bratman, Theodorus van der Kwast, Trevor Pugh, Anthony M Joshua, Daniel D De Carvalho, Kim N Chi, Philip Awadalla, G
信号转导
肿瘤
表观遗传
前列腺癌
其它细胞
DNA甲基化
发表日期：2022
文献求助 收藏

Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer

脂质组学和基因异常对转移性去势抵抗性前列腺癌临床结局的综合影响

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-022-02298-0
Mak, Blossom; Lin, Hui-Ming; Kwan, Edmond M; Fettke, Heidi; Tran, Ben; Davis, Ian D; Mahon, Kate; Stockler, Martin R; Briscoe, Karen; Marx, Gavin; Zhang, Alison; Crumbaker, Megan; Tan, Winston; Huynh, Kevin; Meikle, Thomas G; Mellett, Natalie A; Hoy, Andrew J; Du, Pan; Yu, Jianjun; Jia, Shidong; Joshua, Anthony M; Waugh, David J; Butler, Lisa M; Kohli, Manish; Meikle, Peter J; Azad, Arun A; Horvath, Lisa G
肿瘤
前列腺癌
肿瘤免疫
发表日期：2022
文献求助 收藏

Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER

在接受恩扎卢胺治疗的去势抵抗性前列腺癌患者中，他汀类药物和二甲双胍的使用与预后的关系：AFFIRM、PREVAIL 和 PROSPER 研究的荟萃分析

期刊:European Journal of Cancer
影响因子:7.1
doi:10.1016/j.ejca.2022.04.005
Joshua, Anthony M; Armstrong, Andrew; Crumbaker, Megan; Scher, Howard I; de Bono, Johann; Tombal, Bertrand; Hussain, Maha; Sternberg, Cora N; Gillessen, Silke; Carles, Joan; Fizazi, Karim; Lin, Ping; Duggan, William; Sugg, Jennifer; Russell, David; Beer, Tomasz M
肿瘤
前列腺癌
肿瘤免疫
发表日期：2022
文献求助 收藏

GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)

GUIDE：一项随机、非对照 II 期试验，比较生物标志物驱动的间歇性多西他赛与标准治疗多西他赛在转移性去势抵抗性前列腺癌中的疗效（临床试验方案）

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359221092486
Conduit, Ciara; Mak, Blossom; Qu, Wenjia; Lulio, Juliana Di; Burder, Ronan; Bressel, Matthias; Cusick, Thomas; Dhillon, Haryana M; Lourenço, Richard De Abreu; Underhill, Craig; Torres, Javier; Crumbaker, Megan; Honeyball, Florian; Linton, Anthony; Allen, Ray; Davis, Ian D; Clark, Susan J; Horvath, Lisa G; Mahon, Kate L
肿瘤
前列腺癌
肿瘤免疫
IDE
发表日期：2022
文献求助 收藏